Form 4: Contineum CSO Exercises Options, Sells Shares

Contineum Therapeutics' Chief Scientific Officer, Daniel S. Lorrain, exercised stock options and subsequently sold an equal number of shares on February 11, 2026, under a pre-arranged 10b5-1 plan.

Summary

• Daniel S. Lorrain, Chief Scientific Officer of Contineum Therapeutics, Inc. (CTNM), engaged in transactions involving Class A Common Stock.
• On February 11, 2026, Lorrain acquired 400 shares of Class A Common Stock through the exercise of stock options at a price of $1.01 per share.
• Immediately following, on the same date, Lorrain disposed of 400 shares of Class A Common Stock at a price of $16.00 per share.
• These transactions were executed under a Rule 10b5-1 trading plan established on September 23, 2025.
• Following these transactions, Lorrain directly beneficially owns 156,052 shares of Class A Common Stock and indirectly owns 6,842 shares via his spouse.
• 75,530 stock options remain beneficially owned directly, which are fully vested and exercisable.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While an insider sale can sometimes be a concern, the execution under a 10b5-1 plan indicates a pre-planned compensation-related transaction, and the significant profit realized by the CSO is a positive for the individual.

Positives

• Chief Scientific Officer Daniel S. Lorrain realized a significant profit by exercising stock options at $1.01 per share and selling the shares at $16.00 per share.
• The transactions were conducted under a pre-established 10b5-1 trading plan, indicating planned and transparent insider trading activity.

Negatives

• Chief Scientific Officer Daniel S. Lorrain sold 400 shares of Class A Common Stock, which could be perceived as a lack of confidence by some investors, despite being part of a pre-arranged plan.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that routine insider transactions under 10b5-1 plans are common across the biotechnology and pharmaceutical sectors, often reflecting executive compensation structures rather than a direct signal about company performance. These plans help insiders manage their equity holdings while avoiding accusations of trading on material non-public information.

Stakeholder Impact

• Shareholders: May view the insider sale with slight caution, but the 10b5-1 plan mitigates concerns. The profit realized by the CSO could be seen as a positive for executive incentives.

Key Dates

Recommendation

This Form 4 reports a routine insider transaction under a pre-established 10b5-1 plan. While the Chief Scientific Officer sold shares, it was part of a planned compensation event, not necessarily a signal of a change in company fundamentals or outlook. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Contineum Therapeutics, CTNM, Form 4, Insider Trading, Stock Options, Share Sale, 10b5-1 Plan, Daniel S. Lorrain, Chief Scientific Officer